

DAFTAR PUSTAKA

- Abdassah, M., Noviardani, T., Levita, J., & Suherman, S. E. (2020). Formulasi dan Uji Stabilitas Tetes Mata Sulfasetamida. *Jurnal Ilmu Farmasi dan Klinik*, 2(1), 33–40.
- Ariani, R., et al. (2018). *Formulasi dan Evaluasi Stabilitas Sediaan Insulin dengan Basis Polimer Hidrogel*. *Jurnal Ilmu Kefarmasian Indonesia*, 16(1), 43–49.
- Aynsley TR. The use of insulin in the treatment of corneal ulcers. *Br J Ophthalmol*. 1945;29(7):361–363.
- Aynsley, T.R. The use of insulin in the treatment of corenal ulcers. *Br. J. Ophthalmol*. **1945**, 29, 361–363.
- Balal, S.; Din, N.; Ashton, C.; Ahmad, S. Healing of Chemical Injury-Related Persistent Corneal Epithelial Defects with Topical Insulin. *Cornea* **2023**, 42, 1000–1004.
- Bartlett, J.D.; Slusser, T.G.; Turner-Henson, A.; Singh, K.P.; Atchison, J.A.; Pillion, D.J. Toxicity of insulin administered chronically to human eye in vivo. *J. Ocul. Pharmacol*. **1994**, 10, 101–107.
- Bartlett, J.D.; Turner-Henson, A.; Atchison, J.A.; Woolley, T.W.; Pillion, D.J. Insulin administration to the eyes of normoglycemic human volunteers. *J. Ocul. Pharmacol*. **1994**, 10, 683–690.
- Bastion, M.L. et al. (2024). *Clinical outcome of topical insulin for diabetic corneal healing*. *International Journal of Ophthalmic Therapy*.
- Blair, J., & Milosavljevic, N. (2019). "Ocular drug delivery for the treatment of diabetic retinopathy: Recent advances and future prospects." *Drug Delivery and Translational Research*, 9(3), 619-632.

- Bonini, S., Lambiase, A., Rama, P., *et al.* (2018). Neurotrophic keratitis: a multifactorial disease requiring a multidisciplinary approach. *Eye and Vision*, 5(1), 1-9.
- BPOM RI. (2020). *Cara Pembuatan Obat yang Baik (CPOB) Edisi 2020*. Jakarta: Badan Pengawas Obat dan Makanan.
- Chaiyasan, W., *et al.* (2021). "The role of excipients in ophthalmic formulations: Stability and therapeutic efficacy." *Journal of Pharmaceutical Sciences*.
- Dandona, P., Aljada, A., & Bandyopadhyay, A. (2004). "Insulin as an anti-inflammatory and antiatherogenic effect: Novel actions and therapeutic implications." *Current Opinion in Cardiology*, 19(6), 531-537.
- Denyer, S. P., Hodges, N. A., & Gorman, S. P. (2011). *Hugo and Russell's Pharmaceutical Microbiology*. Wiley-Blackwell.
- Departemen Kesehatan Republik Indonesia. (2020). *Farmakope Indonesia Edisi VI*. Jakarta: BPOM RI.
- Diaz-Valle, D.; Burgos-Blasco, B.; Gegundez-Fernandez, J.A.; Garcia-Caride, S.; Puebla- Garcia, V.; Peña-Urbina, P.; Benitez-DelCastillo, J.M. Topical insulin for refractory persistent corneal epithelial defects. *Eur. J. Ophthalmol.* **2021**, *31*, 2280–2286.
- Diaz-Valle, D.; Burgos-Blasco, B.; Rego-Lorca, D.; Puebla-Garcia, V.; Perez-Garcia, P.; Benitez-Del-Castillo, J.M.; Herrero-Vanrell, R.; Vicario-de-la-Torre, M.; Gegundez-Fernandez, J.A. Comparison of the efficacy of topical insulin with autologous serum eye drops in persistent epithelial defects of the cornea. *Acta Ophthalmol.* **2022**, *100*, e912–e919.
- Esmail, A.; Ibrahim, M.; Nage, S. Efficacy of topical insulin for recurrent epithelial corneal erosions. *Ir. J. Med. Sci.* **2023**, *192*, 3117–3123.
- Guillermo E. Umpierrez, Elizabeth H. Holt, Zachary T. Bloomgarden, Janet B. McGill *Endocrine Practice*, 2020

- Heinemann, L., & Heise, T. (2004). "Insulin aspart: The first modern rapid-acting insulin analog." *Diabetes Technology & Therapeutics*, 6(5), 790-798.
- Hirsch, I. B. (2005). "Intensive treatment of type 1 diabetes." *New England Journal of Medicine*, 352(3), 267-274.
- Jithan AV, Mohan CK, Vimaladevi M. Development and evaluation of a chloramphenicol hypertonic ophthalmic solution. *Indian J Pharm Sci.* 2008 Jan;70(1):66-70. doi: 10.4103/0250-474X.40334. PMID: 20390083; PMCID: PMC2852064.
- Khalaj, M., Barzegar, K., & Naseri, M. (2018). "Potential therapeutic effects of insulin on diabetic keratopathy: A systematic review." *Journal of Diabetes Research*, 2018, 1-8.
- Kumagai, A.K.; Glasgow, B.J.; Pardridge, W.M. GLUT1 glucose transporter expression in the diabetic and nondiabetic human eye. *Investig. Ophthalmol. Vis. Sci.* **1994**, 35, 2887–2894.
- Kumar, S., *et al.* (2019). "Stability and delivery considerations of insulin for ocular application." *Drug Delivery*.
- Lemp, M. A., & Foulks, G. N. (2007). The definition and classification of dry eye disease. *Ocul Surf*, 5(2), 75–92.
- López-Cabezas, C. *et al.* (2023). *Insulin eye drops for treating corneal epithelial defects: Stability study*. Farmacia Hospitalaria, Elsevier.
- Mahajan, S., & Chauhan, M. (2016). "Ocular pharmacokinetics and stability of insulin eye drops in diabetic animal models." *International Journal of Pharmaceutics*, 509(1-2), 182-189.
- Manhas, N. *et al.* (2021). *Topical insulin in ophthalmology: Applications and safety*. Journal of Ophthalmic Research.

- Meduri, A., *et al.* (2020). Topical insulin in the treatment of neurotrophic keratopathy: current perspectives. *Therapeutics and Clinical Risk Management*, 16, 711-718.
- Naeser, P. Insulin receptors in human ocular tissues. Immunohistochemical demonstration in normal and diabetic eyes. *Ups. J. Med. Sci.* **1997**, 102, 35–40.
- Nasution, M., *et al.* (2019). *Pengaruh Penambahan Zinc dan Fenol terhadap Stabilitas Insulin*. Jurnal Farmasi Klinik Indonesia, 8(2), 57–63.
- Patel, S. V., & McLaren, J. W. (2017). "Insulin in ophthalmic drug delivery: Opportunities and challenges." *Cornea*, 36(12), 1515-1521.
- Patel, S. V., & McLaren, J. W. (2017). "Insulin in ophthalmic drug delivery: Opportunities and challenges." *Cornea*, 36(12), 1515-1521.
- Potocka, E., & Paes, B. (2003). "Efficacy and safety of insulin aspart in children and adolescents with type 1 diabetes." *Diabetes Care*, 26(4), 1140-1145.
- Pritchard, N., Edwards, K., Shahidi, A. M., *et al.* (2017). Corneal markers of diabetic neuropathy. *Ocular Surface*, 15(3), 445-461.
- Priyanka, V., Anamika, V., & Abhishek, N. (n.d.). Asian Journal of Pharmaceutical Research and Development REVIEW ON BASIC CONCEPT FOR OPHTHALMIC PREPARATIONS. Asian Journal of Pharmaceutical Research and Development, 3(2), 1–9.
- Raskin, P., & Hollander, P. (2003). "A comparison of insulin aspart and regular human insulin in the treatment of patients with type 2 diabetes mellitus." *Clinical Therapeutics*, 25(3), 885-898.
- Remington, J. P. (2020). *Remington: The Science and Practice of Pharmacy*. Pharmaceutical Press.
- Rocha, E.M.; Cunha, D.A.; Carneiro, E.M.; Boschero, A.C.; Saad, M.J.; Velloso, L.A. *Identification of insulin in the tear film and insulin receptor and IGF-*

- I receptor on the human ocular surface. Investig. Ophthalmol. Vis. Sci.* **2002**, 43, 963–967.
- Sacchetti, M., Lambiase, A., *et al.* (2014). *Diagnosis and management of neurotrophic keratitis. Clinical Ophthalmology*, 8, 571–579.
- Sandle, T. (2019). *Sterility, Sterilisation and Sterility Assurance for Pharmaceuticals: Technology, Validation and Current Regulations*. Elsevier.
- Sari, L. & Lestari, W. (2020). *Studi Stabilitas Sediaan Insulin dalam Penyimpanan Suhu Ruang. Jurnal Farmasi dan Ilmu Kefarmasian Indonesia*, 7(2), 134–141.
- Shanley, L.J.; McCaig, C.D.; Forrester, J.V.; Zhao, M. Insulin, not leptin, promotes in vitro cell migration to heal monolayer wounds in human corneal epithelium. *Investig. Ophthalmol. Vis. Sci.* **2004**, 45, 1088–1094.
- Sheskin, D. J. (2020). *Parametric and nonparametric statistical procedures: Third edition. Handbook of Parametric and Nonparametric Statistical Procedures: Third Edition*, 1–1193.
- Shukla, D., *et al.* (2017). "Stability considerations in ophthalmic formulations: A review." *Ophthalmic Drug Delivery Systems*.
- Stuard, W.L.; Titone, R.; Robertson, D.M. The IGF/Insulin-IGFBP Axis in Corneal Development, Wound Healing, and Disease. *Front. Endocrinol.* **2020**, 11, 24.
- Wang, A.L.; Weinlander, E.; Metcalf, B.M.; Barney, N.P.; Gamm, D.M.; Nehls, S.M.; Struck, M.C. *Use of Topical Insulin to Treat Refractory Neurotrophic Corneal Ulcers. Cornea* **2017**, 36, 1426–1428.
- WHO. (2011). *Guidelines on sterility testing*. Technical Report Series No. 961.
- WHO (2021). *Annex 6: Good Manufacturing Practices for Sterile Pharmaceutical Products*. WHO Technical Report Series. United States Pharmacopeia

(USP) <71> Sterility Tests (2021). European Pharmacopoeia (Ph. Eur.).
Farmakope Indonesia Edisi VI.

Yang, L., Zhang, H., Zhang, C., *et al.* (2020). *Pathophysiology of diabetic corneal complications and emerging treatment strategies. Frontiers in Endocrinology*, 11, 620632.

Zagon, I. S., & McLaughlin, P. J. (2005). "Insulin's effects on wound healing in the cornea: An experimental study." *Investigative Ophthalmology & Visual Science*, 46(10), 3567-3572.

Zhu, W., Hong, J., Zheng, T., *et al.* (2021). *The role of diabetes-induced corneal nerve alterations in neurotrophic keratopathy. Journal of Diabetes Research*, 2021, 8894208.